What changed
What changedOn November 17, 2026, AtriCure announced details for its BoxX-NoAF clinical trial, which evaluates cardiac ablation and left atrial appendage exclusion (LAAE) to lower the risk of atrial fibrillation (Afib). The study targets patients with risk factors but no prior history of Afib.

What changedOn November 11, 2026, AtriCure released results from its three-year CEASE-AF study. The data confirm the long-term effectiveness of hybrid ablation compared to catheter ablation alone.

What changedAtriCure announced the availability of its third-quarter report on November 3, 2026. This allows shareholders to review progress in medical solution development.

What changedAtriCure reported $154,450,000 in revenue for the third quarter of 2026, a 15% increase year-over-year. Net income for the quarter was $4,064,000, compared to a $267,000 loss in the third quarter of 2025.

What changedOn November 3, 2026, AtriCure, Inc. released its third-quarter earnings report. The document highlighted progress in supporting physicians, advancing innovation, and assisting patients globally.

Show all articles (8)
What changedAtriCure, Inc. reported third-quarter 2026 revenue of $154.5 million, up 15.0% year over year. The company's net income was $4.1 million.

What changedOn October 14, Hôpital du Sacré-Coeur de Montréal completed its first surgery using the Isolator Synergy EnCompass clamp from AtriCure. The company also announced it is hiring clinical specialists for its Cryo Nerve Block team.

What changedAtriCure announced the first worldwide use of the Isolator® Synergy™ EnCompass® clamp in Montreal hospitals and unveiled a Hybrid Best Practices Guide developed by 25 authors from 10 countries

Company history
October 2026
AtriCure, Inc.: 12 recorded developments from 9 official sources in 2026-10.
- 2026-10-12: With the cryoSPHERE® MAX probe, each minute means a step closer to post-op pain relief for your cardiac and thoracic patients. Source
- 2026-10-13: The Isolator® Synergy™ EnCompass® clamp delivers real-time, patient specific, adaptive RF energy so surgeons get the same dependable lesion quality, case after case. Less guesswork means more confidence in every application. Source
- 2026-10-14: Dr. Nicolas DÜRRLEMAN, Dr. Almothana Alzamil, and the team at Fondation de l'Hôpital du Sacré-Coeur de Montréal completed their first case with the Isolator® Synergy™ EnCompass® clamp. Source
- 2026-10-14: The EnCompass clamp is available in two sizes — standard and long, giving surgeons the flexibility to match diverse patient anatomy. Source
- 2026-10-14: The EnCompass clamp is available in two sizes — standard and long, giving surgeons the flexibility to match diverse patient anatomy. Source
- 2026-10-14: AtriCure has published a Hybrid Best Practices Guide that brings together insights from 25 authors across 10 countries to help standardize combined epicardial + endocardial Hybrid AF Therapy. Source
- 2026-10-14: The Hybrid Best Practices Guide aims to help more patients achieve lasting rhythm control with Hybrid AF Therapy, described as a durable treatment option for LSPAF. Source
- 2026-10-14: Dr. Dürrleman, Dr. Alzamil, and the team at Hôpital du Sacré-Coeur-de-Montréal completed their first case with the Isolator® Synergy™ EnCompass® clamp. Source
- 2026-10-14: To learn more about the impact of #AFib and possible treatment options, visit: https://okt.to/oCGpNR #AtrialFibrillation Source
- 2026-10-14: Fondation de l'Hôpital du Sacré-Coeur de Montréal completed their first case using the Isolator Synergy EnCompass clamp. Source
- 2026-10-18: AtriCure is hiring Clinical Specialists for its Cryo Nerve Block team to support surgical cases and therapy adoption for post-operative pain management. Source
- 2026-10-23: The BoxX-NoAF trial is evaluating the safety and effectiveness of surgical ablation and left atrial appendage management in non-Afib cardiac surgery patients to reduce the incidence of POAF and long-term clinical Afib. Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Expectations and reality
How expectations played out
1 of 6 expectations checked against later reports
Mostly AI assessments, provisional; an editor's decision replaces them. Not a rating of the shares.
Checked against later reports
The company expects to complete site initiation and enrollment for the BoxX-NoAF trial.
Said November 4, 2026 · Period named: fourth quarter of 2026 · Source · Our article
AI assessment, provisional later reports are consistent with it (as of November 17, 2026) · Later article
Open
Full year 2026 revenue is projected to be approximately $606 million to $610 million.
Said November 3, 2026 · Period named: Full year 2026 · Source · Our article
Not yet checked against later reports.
Full year 2026 net income per share is expected to be in the range of $0.21 to $0.27.
Said November 3, 2026 · Period named: Full year 2026 · Source · Our article
Not yet checked against later reports.
Full year 2026 adjusted EBITDA is projected to be approximately $91 million to $94 million.
Said November 3, 2026 · Period named: Full year 2026 · Source · Our article
Not yet checked against later reports.
Management expects continued positive cash generation.
Said November 3, 2026 · Period named: 2026 · Source · Our article
Not yet checked against later reports.
Full year 2026 adjusted earnings per share is projected to be approximately $0.40 to $0.46.
Said November 3, 2026 · Period named: Full year 2026 · Source · Our article
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Changes in risk factors
The 10-Q filed November 4, 2026 compared with the 10-Q filed July 27, 2026: risk paragraphs that were added or dropped, quoted as filed. SEC
Added (3)
- Research and development expenses. Research and development expenses increased $9,224, or 40.3%, primarily driven by a $4,500 milestone payment for acquired IPR&D made in the third quarter of 2026; $3,038 increase in clinical activity costs, largely attributable to BoxX-NoAF trial enrollment; and $1,579 incremental investment in our product pipeline through new product development projects.
- Cash flows used in investing activities. Net cash used in investing activities increased by $6,558 from 2025 to 2026, driven by higher capital expenditures related to the facilities expansion on our corporate headquarters campus in Mason, Ohio.
- Cash flows used in financing activities. Net cash used in financing activities increased by $9,097 from 2025 to 2026 and was driven primarily by the $6,250 non-recurring proceeds from the 2025 failed sale-and-leaseback transaction. Other increases included debt-related payments of $1,787 and shares repurchased for payment of taxes on stock awards of $1,364.
Dropped (2)
- Cash flows used in investing activities. Net cash used in investing activities improved by $1,725 from 2025 to 2026, due to the decrease of $5,000 for the 2025 acquired IPR&D milestone payment, offset by a $2,775 increase in purchases of property and equipment and $500 in capital grant proceeds received in 2025.
- Cash flows used in financing activities. Net cash used in financing activities increased by $3,087 from 2025 to 2026. This increase was a result of $777 cash used to pay financing costs as part of the First Amendment to the ABL Facility, $865 paid to reduce outstanding borrowings and a $1,178 increase in shares repurchased for payment of taxes on stock awards.
Found by comparing the two reports paragraph by paragraph, without AI. A new or dropped risk is not by itself a sign of trouble.
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|
| BlackRock | 7,943,332 | $446,415,259 | +77.5% | Q3 2026 |
| Wellington Management | 4,116,204 | $231,330,666 | +17.8% | Q3 2026 |
| State Street | 2,128,807 | $119,638,953 | +53.2% | Q3 2026 |
| Geode Capital Management | 1,303,089 | $73,248,248 | -1.3% | Q3 2026 |
| Fidelity (FMR) | 606,555 | $34,088,385 | +19.8% | Q3 2026 |
| Citadel Advisors | 567,483 | $31,892,544 | +220.0% | Q3 2026 |
| D. E. Shaw & Co. | 325,684 | $18,303,441 | +68.9% | Q3 2026 |
| Renaissance Technologies | 321,000 | $18,040,200 | +37.1% | Q3 2026 |
| Two Sigma Investments | 525,795 | $14,711,744 | -30.0% | Q2 2026 |
| Norges Bank (Norway's sovereign fund) | 374,362 | $10,474,649 | — | Q2 2026 |
| Millennium Management | 179,886 | $5,132,148 | — | Q1 2026 |
| Bridgewater Associates | 42,194 | $2,371,303 | -44.7% | Q3 2026 |
| T. Rowe Price | 72,693 | $4,086 | -0.5% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.